Global Fund For Antimicrobial Resistance Proposed, Financing Unclear
This article was originally published in The Pink Sheet Daily
The U.K.’s Review on Antimicrobial Resistance, led by leading health economist Jim O’Neill, has come up with initial proposals to tackle the problem, with final conclusions expected in the summer of 2016.
You may also be interested in...
New Report Calls For Pushing And Pulling In Global Fight Against Superbugs
New DRIVE-AB report on revitalizing antibiotic R&D suggests market-entry rewards of up to $1bn for companies introducing novel products, cites need for increasing public funding of R&D support.
Antibiotic Incentives Helped Spero Get Where It Is Today
The firm is developing a novel class of antibacterials that could enable shelved agents for Gram-positive infections to reach and kill Gram-negative bacteria.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.